Trident-1 A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) (Aktiv)
Erstlinie
GSK-213824 A Phase 2, Randomized, Open-label, Platform Study Utilizing a Master Protocol to Evaluate Novel Immunotherapy Combinations in Participants with Previously Untreated, Locally Advanced/Metastatic, Programmed Death Ligand 1-Selected Non-Small-Cell Lung Cancer (Aktiv)
LIBRETTO-432 (J2G-MC-JZJX) A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) (Aktiv)
PALOMA-2 A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in multiple regimens in patients with Advanced or Metastatic Solid Tumors including EGFR mutated NSCLC (PALOMA-2) (Aktiv)
TROPION-Lung08 A randomized open-label phase 3 trial of Dato-DXd plus Pembrolizumab vs Pembrolizumab alone in treatment naïve subjects with advanced or metastatic PD-L1 High (TPS>= 50%) NSCLC without actionable genomic alterations (Tropion-LUNG08) (Aktiv)